These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 17551159)
1. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ; N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159 [TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Home PD; Pocock SJ; Beck-Nielsen H; Curtis PS; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ; Lancet; 2009 Jun; 373(9681):2125-35. PubMed ID: 19501900 [TBL] [Abstract][Full Text] [Related]
3. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G; Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone and cardiotoxicity--weighing the evidence. Nathan DM N Engl J Med; 2007 Jul; 357(1):64-6. PubMed ID: 17551161 [No Abstract] [Full Text] [Related]
5. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532 [TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Dahabreh IJ; Economopoulos K Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649 [TBL] [Abstract][Full Text] [Related]
7. Cancer and bone fractures in observational follow-up of the RECORD study. Jones NP; Curtis PS; Home PD Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432 [TBL] [Abstract][Full Text] [Related]
8. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Singh S; Loke YK; Furberg CD JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653 [TBL] [Abstract][Full Text] [Related]
9. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611 [TBL] [Abstract][Full Text] [Related]
10. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records. Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784 [TBL] [Abstract][Full Text] [Related]
11. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780 [TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL; Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320 [TBL] [Abstract][Full Text] [Related]
13. [Rosiglitazone: no increase in cardiovascular mortality]. Jazet IM; Meinders AE Ned Tijdschr Geneeskd; 2009; 153():A942. PubMed ID: 19930745 [TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036 [TBL] [Abstract][Full Text] [Related]
15. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894 [TBL] [Abstract][Full Text] [Related]
16. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614 [TBL] [Abstract][Full Text] [Related]
17. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Komajda M; McMurray JJ; Beck-Nielsen H; Gomis R; Hanefeld M; Pocock SJ; Curtis PS; Jones NP; Home PD Eur Heart J; 2010 Apr; 31(7):824-31. PubMed ID: 20118174 [TBL] [Abstract][Full Text] [Related]